Access to anti-retroviral drugs, female (%) in Syria
Syria: Access to anti-retroviral drugs, female (%) was 41.0% in 2024. ◆ Volatile
Access to anti-retroviral drugs, female in Syria, 2000–2024
Source: UNAIDS estimates. Measured in %.
Analysis
In 2024, access to anti-retroviral drugs, female in Syria stood at 41.0%.
The figure is up 2.5% on the previous year and up 57.7% over ten years.
Over the whole period, access to anti-retroviral drugs, female in Syria peaked at 44.0% in 2020 and was at its lowest, 0.0%, in 2000.
Syria ranks 127th of 141 countries on this measure, in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Access to anti-retroviral drugs, female (%) in Syria, year by year
| Year | % | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 3.0% | — |
| 2004 | 6.0% | +100.0% |
| 2005 | 7.0% | +16.7% |
| 2006 | 6.0% | -14.3% |
| 2007 | 8.0% | +33.3% |
| 2008 | 11.0% | +37.5% |
| 2009 | 13.0% | +18.2% |
| 2010 | 14.0% | +7.7% |
| 2011 | 16.0% | +14.3% |
| 2012 | 20.0% | +25.0% |
| 2013 | 22.0% | +10.0% |
| 2014 | 26.0% | +18.2% |
| 2015 | 27.0% | +3.8% |
| 2016 | 29.0% | +7.4% |
| 2017 | 34.0% | +17.2% |
| 2018 | 38.0% | +11.8% |
| 2019 | 43.0% | +13.2% |
| 2020 | 44.0% | +2.3% |
| 2021 | 43.0% | -2.3% |
| 2022 | 39.0% | -9.3% |
| 2023 | 40.0% | +2.6% |
| 2024 | 41.0% | +2.5% |
Syria compared with similar countries
- Syria's 41.0% is below the median for low income countries, which is 75.5%, 54% of the median. (24 countries reporting)
- Syria's 41.0% is below the median for Middle East, North Africa, Afghanistan & Pakistan, which is 55.0%, 75% of the median. (20 countries reporting)
Biggest year-on-year movements
Years where Access to anti-retroviral drugs, female (%) in Syria changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2004 | +100.0% | 3.0% | 6.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 5.4% | 0.0% | 13.0% | 10 |
| 2010s | 26.9% | 14.0% | 43.0% | 10 |
| 2020s | 41.4% | 39.0% | 44.0% | 5 |
Countries ranked near Syria
More gender data for Syria
- Child population (UN estimates and projections) 8,107 (2030)
- Child population (UN estimates and projections) (0-14), annual growth 3.23 % change on previous year (2030)
- Population 21,289 (2030)
- Working-age population (UN estimates and projections) 21,289 (2030)
- Population (UN estimates and projections), annual growth rate 2.03 % change on previous year (2030)
- Age population, age 00, female, interpolated 288,104 (2025)
- Age population, age 00, male, interpolated 302,347 (2025)
- Age population, age 01, female, interpolated 273,777 (2025)
- Age population, age 01, male, interpolated 287,191 (2025)
- Age population, age 02, female, interpolated 255,304 (2025)
Frequently asked questions
- What is access to anti-retroviral drugs, female in Syria?
- Access to anti-retroviral drugs, female in Syria was 41.0% in 2024, according to UNAIDS estimates.
- What is the highest access to anti-retroviral drugs, female recorded in Syria?
- The highest recorded value was 44.0% in 2020.
- What is the lowest access to anti-retroviral drugs, female recorded in Syria?
- The lowest recorded value was 0.0% in 2000.
- How does Syria rank for access to anti-retroviral drugs, female?
- Syria ranks 127th out of 141 countries with data for 2024.
- Is access to anti-retroviral drugs, female rising or falling in Syria?
- Over the last ten years it is up 57.7%. The long-run trend across the full record is volatile.
- Where does this Syria data come from?
- The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.